The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors.
 
Jong Chul Park
Research Funding - A2 Biotherapeutics (Inst); ALX Oncology (Inst); Ankyra Therapeutics (Inst); Inhibrx (Inst)
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche; Sanofi
Consulting or Advisory Role - Adaptimmune; Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; IDEAYA Biosciences; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; LaRoche Posay; Medison; Merck; Novartis; Pfizer; Regeneron; Sanofi; Sun Pharma
Research Funding - Merck (Inst); Novartis Canada Pharmaceuticals Inc (Inst); Takara Bio (Inst)
Expert Testimony - Merck
 
Brendan D. Curti
Honoraria - Clinigen Group; Sanofi
Consulting or Advisory Role - Merck
Research Funding - Bristol-Myers Squibb (Inst); Clinigen Group (Inst)
Patents, Royalties, Other Intellectual Property - Biomarkers for OX40 response (Inst)
 
Leisha A. Emens
Employment - Ankyra Therapeutics
Leadership - Society for Immunotherapy of Cancer; Society for Immunotherapy of Cancer; Society for Immunotherapy of Cancer
Stock and Other Ownership Interests - Ankyra Therapeutics; Molecuvax
Consulting or Advisory Role - Abbvie; BiolineRx; Bristol Meyers Squibb; Chugai Pharma; CytomX Therapeutics; DNAMx; Genentech/Roche; Gilead Sciences; GPCR Therapeutics; Immune-Onc Therapeutics; Immunitas; Immutep; Macrogenics; Mersana; Molecuvax; Replimune; Shionogi; Silverback Therapeutics
Research Funding - Abbvie; Aduro Biotech; AstraZeneca; Bolt Biotherapeutics; Bristol Myers Squibb; Compugen; Corvus Pharmaceuticals; CytomX Therapeutics; EMD Serono; Genentech; Immune-Onc Therapeutics; Maxcyte; Merck; NextCure; Roche; Silverback Therapeutics; Takeda; Tempest Therapeutics
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech; Roche
Other Relationship - Aduro Biotech
 
Danielle M. Pastor
No Relationships to Disclose
 
Joseph Elassal
Employment - Ankyra Therapeutics
Leadership - Ankyra Therapeutics
Stock and Other Ownership Interests - Ankyra Therapeutics
Travel, Accommodations, Expenses - Ankyra Therapeutics
 
Howard L. Kaufman
Employment - Ankyra Therapeutics
Leadership - Ankyra Therapeutics
Stock and Other Ownership Interests - Immuneering; Replimune
Honoraria - Society for Immunotherapy of Cancer
Consulting or Advisory Role - Castle Biosciences; Marengo Therapeutics; Midatech Pharma; Tatum Bioscience; Virogin Biotech
 
John M. Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen; Ankyra Therapeutics; Applied Clinical Intelligence; AXIO Research; Becker Pharmaceutical Consulting; Bristol Myers Squibb; Cancer Network; Cancer Study Group; Checkmate Pharmaceuticals; CytomX Therapeutics; DermTech; Fenix Group International; Harbour BioMed; Immunocore; iOnctura; Iovance Biotherapeutics; IQVIA; Istari Oncology; Jazz Pharmaceuticals; Lytix Biopharma; Magnolia Innovation; Merck; Natera; Novartis; OncoCyte; OncoSec; PATHAI; Pfizer; Piper Sandler; PyrOjas Corporation; Regeneron; Replimune; Scopus BioPharma; SR One Capital Management; Takeda; Valar Labs
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Lion Biotechnologies (Inst); Novartis (Inst); Takeda (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ankyra Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Iovance Biotherapeutics; Regeneron